Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
14 search results for:

Ramucirumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 08-06-2022 | ASCO 2022 | Conference coverage | Article

    Lung-MAP: Post-immunotherapy ramucirumab plus pembrolizumab improves NSCLC survival

    Ramucirumab plus pembrolizumab significantly improves overall survival versus standard of care in people with advanced non-small-cell lung cancer previously treated with immunotherapy and chemotherapy, phase 2 Lung-MAP Protocol substudy data show.

    Author:
    Laura Cowen
    Published in:
    2022 ASCO Annual Meeting; Chicago, Illinois, USA: 3–7 June
  2. 18-06-2020 | ASCO 2020 | Conference coverage | Article

    Ramucirumab–gemcitabine encouraging in second-line malignant pleural mesothelioma

    Adding ramucirumab to gemcitabine may significantly improve survival outcomes for patients with malignant pleural mesothelioma who have progressed on first-line platinum–pemetrexed regimens, suggest findings from the phase 2 RAMES study presented at the virtual 2020 ASCO Annual Meeting.

    Author:
    Hannah Kitt
    Published in:
    2020 ASCO Annual Meeting; 29–31 May
  3. 20-01-2020 | EMA | News | Article
    approvalsWatch

    First-line ramucirumab–erlotinib supported by EMA for metastatic NSCLC

    medwireNews : The EMA has adopted a positive opinion  recommending use of the VEGFR2 inhibitor ramucirumab as a first-line treatment for metastatic non-small-cell lung cancer (NSCLC) alongside the EGFR inhibitor erlotinib.

    Author:
    Lynda Williams
  4. 28-11-2019 | Urothelial cancer | News | Article

    Adding ramucirumab to docetaxel improves PFS but not OS in advanced urothelial cancer

    Updated results from the RANGE trial support improved progression-free survival with the addition of ramucirumab to docetaxel in patients with platinum-refractory advanced urothelial carcinoma, but show no significant overall survival benefit.

    Published in:
    Lancet Oncol 2019; doi:10.1016/S1470-2045(19)30668-0 Lancet Oncol 2019; doi: doi.org/10.1016/S1470-2045(19)30661-8
  5. 11-06-2019 | Non-small-cell lung cancer | News | Article

    RELAY: Ramucirumab–erlotinib a potential first-line option for EGFR-mutated NSCLC

    Combining erlotinib with ramucirumab significantly improves the progression-free survival of untreated patients with advanced EGFR mutation-positive non-small-cell lung cancer, suggest phase III results presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

    Published in:
    2019 ASCO Annual Meeting; Chicago, Illinois, USA: 31 May–4 June
  6. 25-07-2017 | Colorectal cancer | Article

    Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial

    Cohn AL et al. Cancer Chemother Pharmacol . 2017; 80: 599. doi:10.1007/s00280-017-3380-z

  7. 15-09-2021 | Non-small-cell lung cancer | News | Article

    No overall survival benefit with first-line bevacizumab–erlotinib in EGFR-mutant NSCLC

    Maemondo et al note that there are three ongoing phase 3 trials of VEGF- and VEGFR-targeted monoclonal antibodies with EGFR–tyrosine kinase inhibitors in patients with advanced EGFR -mutated NSCLC, namely the BEVERLY and CTONG 1509 trials of bevacizumab plus erlotinib and the RELAY trial of ramucirumab plus erlotinib.

    Author:
    Hannah Kitt
    Published in:
    Lancet Respir Med 2021; doi:10.1016/S2213-2600(21)00166-1
  8. 16-07-2019 | Ramucirumab | News | Article

    Phase I data support dual VEGFR2, PD-1 inhibition

    Phase I study data suggest that ramucirumab plus pembrolizumab is a feasible treatment option for patients with previously treated advanced non-small-cell lung cancer, urothelial carcinoma, and gastric or gastroesophageal junction adenocarcinoma.

    Published in:
    Lancet Oncol 2019; doi:10.1016/S1470-2045(19)30458-9
  9. play
    25-09-2017 | Urothelial cancer | ESMO 2017 | Video

    ESMO 2017: RANGE trial results

    Daniel Petrylak outlines the RANGE trial results for use of ramucirumab in patients with advanced urothelial carcinoma. Read the accompanying news story.

  10. 21-04-2017 | Immunotherapy | News | Article

    Caution needed when using PFS as an OS surrogate in immunotherapy trials

    The discrepancy between PFS and OS was especially pronounced for certain drugs, such as obinutuzumab (rHR=0.21), bevacizumab (rHR=0.75), rituximab (rHR=0.79), and ramucirumab (rHR=0.82), whereas the treatment effect sizes did not differ for other drugs, including alemtuzumab (rHR=0.94), cetuximab (rHR=0.96), ipilimumab (rHR=0.95), and trastuzumab (rHR=0.96).

    Published in:
    J Clin Oncol 2017; Advance online publication
  11. 06-12-2016 | Colorectal cancer | Article

    From tumour heterogeneity to advances in precision treatment of colorectal cancer

    In the past few years, other targeted drugs have demonstrated a benefit over standard care, such as aflibercept (a decoy receptor for VEGF-A, VEGF-B and PIGF) and ramucirumab (an antibody against VEGFR-2), both in combination with chemotherapy in the second-line setting, and regorafenib (a multikinase inhibitor) as monotherapy in the refractory setting 34, 35, 36 .

    Author:
    Cornelis J. A. Punt, Miriam Koopman, Louis Vermeulen
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.